keyword
MENU ▼
Read by QxMD icon Read
search

Nonsmall lung cancer

keyword
https://www.readbyqxmd.com/read/29893612/opioid-dose-and-survival-of-patients-with-incurable-nonsmall-cell-lung-cancer-a-prospective-cohort-study
#1
Takaaki Hasegawa, Tetsuya Oguri, Tomohiro Osawa, Toshiyuki Sawa, Satoshi Osaga, Toru Okuyama, Megumi Uchida, Ken Maeno, Satoshi Fukuda, Hirotada Nishie, Akio Niimi, Tatsuo Akechi
BACKGROUND: Preclinical studies show that opioids promote angiogenesis, tumor progression, and metastasis, resulting in shorter survival. OBJECTIVE: To explore whether opioids are associated with the overall survival (OS) of patients with incurable nonsmall cell lung cancer (NSCLC). DESIGN: Prospective cohort study of patients with NSCLC. SETTING: We investigated patients newly diagnosed with advanced or post-operative recurrent NSCLC between April 2013 and December 2015 at a single institute...
June 12, 2018: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/29879078/treatment-rationale-and-design-of-the-spiral-study-a-phase-ii-trial-of-osimertinib-in-elderly-epidermal-growth-factor-receptor-t790m-positive-nonsmall-cell-lung-cancer-patients-who-progressed-during-prior-egfr-tki-treatment
#2
Junji Uchino, Akira Nakao, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada, Kenichi Yoshimura, Masaki Fujita, Koichi Takayama
BACKGROUND: Advances in epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment led to research on the mechanism of the resistance have revealed that an occurrence of T790M gene mutation generated in exon 20 of the EGFR gene is associated with approximately 50% to 60% of observed resistance. Osimertinib, a 3rd-generation EGFR-TKI, has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations. In this study, we prospectively investigate the efficacy and safety of osimertinib in elderly patients aged ≥75 years, with ineffective prior EGFR-TKI treatment or with recurrence of EGFR-TKI mutation-positive or T790M mutation-positive nonsmall-cell lung cancer...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29871545/safety-of-dose-reduced-pemetrexed-in-patients-with-renal-insufficiency
#3
Jordan Hill, Craig Vargo, Michael Smith, Jessica Streeter, David P Carbone
Purpose Pemetrexed has been shown to be effective in the treatment of advanced and metastatic nonsquamous nonsmall cell lung cancer. In this population, renal insufficiency is common; however, pemetrexed is not recommended in patients with a creatinine clearance (CrCl) < 45 ml/min due to increased myelosuppression reported in phase I trials. The primary objective of this study is to determine the safety of dose-reduced pemetrexed in patients with a CrCl < 45 ml/min. Methods This is a retrospective case series describing the incidence of grade 3 or higher toxicity in patients with CrCl < 45 ml/min treated with dose-reduced pemetrexed at The James Cancer Hospital and Solove Research Institute at The Ohio State University...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29866840/phip-as-a-therapeutic-target-for-driver-negative-subtypes-of-melanoma-breast-and-lung-cancer
#4
David de Semir, Vladimir Bezrookove, Mehdi Nosrati, Altaf A Dar, Clayton Wu, Julia Shen, Christopher Rieken, Meenakshi Venkatasubramanian, James R Miller, Pierre-Yves Desprez, Sean McAllister, Liliana Soroceanu, Robert J Debs, Nathan Salomonis, Dirk Schadendorf, James E Cleaver, Mohammed Kashani-Sabet
The identification and targeting of key molecular drivers of melanoma and breast and lung cancer have substantially improved their therapy. However, subtypes of each of these three common, lethal solid tumors lack identified molecular drivers, and are thus not amenable to targeted therapies. Here we show that pleckstrin homology domain-interacting protein (PHIP) promotes the progression of these "driver-negative" tumors. Suppression of PHIP expression significantly inhibited both tumor cell proliferation and invasion, coordinately suppressing phosphorylated AKT, cyclin D1, and talin1 expression in all three tumor types...
June 4, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29845745/the-significant-influence-of-having-children-on-the-postoperative-prognosis-of-patients-with-nonsmall-cell-lung-cancer-a-propensity-score-matched-analysis
#5
Shinkichi Takamori, Tetsuzo Tagawa, Gouji Toyokawa, Hiroki Ueo, Mototsugu Shimokawa, Fumihiko Kinoshita, Taichi Matsubara, Yuka Kozuma, Naoki Haratake, Takaki Akamine, Masakazu Katsura, Kazuki Takada, Fumihiko Hirai, Fumihiro Shoji, Tatsuro Okamoto, Yoshinao Oda, Yoshihiko Maehara
The aim of this study was to elucidate the relationship between family-associated factors and the postoperative prognosis in patients with nonsmall cell lung cancer (NSCLC). Additionally, we investigated whether having children was associated with the postoperative maintenance of the nutritional status. We selected 438 NSCLC patients who had undergone curative lung resection between 2004 and 2011 at Kyushu University (Fukuoka, Japan), whose family-associated factors were available. Nutritional indices, including the prognostic nutritional index (PNI), were used to estimate the change in the nutritional status for 1 year after surgery...
May 29, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29797475/clinical-value-of-jointly-detection-pleural-fluid-midkine-pleural-fluid-adenosine-deaminase-and-pleural-fluid-carbohydrate-antigen-125-in-the-identification-of-nonsmall-cell-lung-cancer-associated-malignant-pleural-effusion
#6
Fan Zhang, Junjun Wang, Xiaoyong Zheng, Lijuan Hu, Jie Chen, Feng Jiang, Yumin Wang
BACKGROUND: Midkine (MK) level has been shown to be elevated in serum of patients with nonsmall cell lung cancer (NSCLC). However, the diagnostic value of MK in pleural effusion in NSCLC has not been well validated and established. METHODS: Samples of NSCLC-associated malignant pleural effusions (MPE) and benign effusions (BPE) were collected. The pleural fluid MK (pMK), pleural fluid adenosine deaminase (pADA), pleural fluid lactate dehydrogenase (pLDH), pleural fluid glucose (pGLU), pleural fluid ferritin (pFER), pleural fluid CA199 (pCA199), pleural fluid CA125 (pCA125), pleural effusion white cell count (pWBC), and pleural effusion red cell count (pRBC) were analyzed, and the clinical data of each group were collected for statistical analysis...
May 23, 2018: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/29790668/the-effects-of-aberrant-expression-of-lncrna-dgcr5-mir-873-5p-tusc3-in-lung-cancer-cell-progression
#7
Judong Luo, Hong Zhu, Hua Jiang, Yayun Cui, Mengjie Wang, Xinye Ni, Changsheng Ma
Lung cancer is the most common cause of cancer-related mortality worldwide, and nonsmall cell lung cancer (NSCLC) accounts for 80% of all pulmonary carcinomas. Recently, long noncoding RNAs (lncRNAs) have been paid attention for exploring treatment of various diseases. Upregulation of DiGeorge syndrome critical region gene 5 (DGCR5) predicts better lung squamous cell carcinoma prognosis; therefore, we explore the role of DGCR5 in lung cancer in our present study. Consecutive patients with LC were treated in our hospital between January 2015 and January 2016...
May 23, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29788766/design-synthesis-and-3d-qsar-based-pharmacophore-study-of-novel-imatinib-analogs-as-antitumor-apoptotic-agents
#8
Iten M Fawzy, Khairia M Youssef, Deena S Lasheen, Nasser Sm Ismail, Khaled Am Abouzid
AIM: Imatinib possesses various mechanisms for combating cancer, making the development of imatinib analogs an attractive target for cancer research. METHOD: Two series of analogs were designed and synthesized, maintaining the essential pharmacophoric features in imatinib structure. The synthesized compounds were subjected to cell-based antiproliferative assays against nonsmall lung (A549) and colon cancer cell lines. In addition, flow cytometry cell cycle and caspase-3 colorimetric assays were performed...
May 23, 2018: Future Medicinal Chemistry
https://www.readbyqxmd.com/read/29772692/insurance-coverage-policies-for-pharmacogenomic-and-multi-gene-testing-for-cancer
#9
Christine Y Lu, Stephanie Loomer, Rachel Ceccarelli, Kathleen M Mazor, James Sabin, Ellen Wright Clayton, Geoffrey S Ginsburg, Ann Chen Wu
Insurance coverage policies are a major determinant of patient access to genomic tests. The objective of this study was to examine differences in coverage policies for guideline-recommended pharmacogenomic tests that inform cancer treatment. We analyzed coverage policies from eight Medicare contractors and 10 private payers for 23 biomarkers (e.g., HER2 and EGFR ) and multi-gene tests. We extracted policy coverage and criteria, prior authorization requirements, and an evidence basis for coverage. We reviewed professional society guidelines and their recommendations for use of pharmacogenomic tests...
May 16, 2018: Journal of Personalized Medicine
https://www.readbyqxmd.com/read/29767438/serum-sp70-is-a-sensitive-predictor-of-chemotherapy-response-in-patients-with-advanced-nonsmall-cell-lung-cancer
#10
Jingping Liu, Wei Zhang, Min Gu, Yazhou Ji, Lu Yang, Xiangjun Cheng, Xuelian Xiao, Jian Xu, Chunrong Gu, Jiexin Zhang, Shichang Zhang, Dan Chen, Shiyang Pan
SP70 is a novel tumor biomarker in patients with nonsmall cell lung cancer (NSCLC). However, its role as a marker for predicting the response to chemotherapy for patients with advanced NSCLC has not been investigated. A total of 152 patients were enrolled. Serum SP70, carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), and neuron-specific enolase (NSE) were detected before and after 2 cycles of chemotherapy. The correlation between serum tumor biomarker levels and chemotherapy responses and their association with epidermal growth factor receptor (EGFR) mutation status and progression-free survival (PFS) were analyzed...
May 16, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29765975/relationship-of-snp-rs2645429-in-farnesyl-diphosphate-farnesyltransferase-1-gene-promoter-with-susceptibility-to-lung-cancer
#11
Mehdi Dehghani, Zahra Samani, Hassan Abidi, Leila Manzouri, Reza Mahmoudi, Saeed Hosseini Teshnizi, Mohsen Nikseresht
Background and Purpose: The mevalonate pathway is one of the major metabolic pathways that use acetyl-CoA to produce sterols and isoprenoids. These compounds can be effective in the growth and development of tumors. One of the enzymes involved in the mevalonate pathway is FDFT1. Different variants of this gene are involved in the risk of suffering various diseases. The present study examined the relationship between FDFT1 rs2645429 polymorphism and the risk of nonsmall cell lung cancer (NSCLC) in a population from southern Iran...
2018: International Journal of Genomics
https://www.readbyqxmd.com/read/29744296/plasma-anti-birc5-igg-may-be-a-useful-marker-for-evaluating-the-prognosis-of-nonsmall-cell-lung-cancer
#12
Huan Zhao, Xuan Zhang, Zhifeng Han, Zhenqi Wang, Yao Wang
A recent study demonstrated that circulating levels of IgG antibodies against linear peptide antigens derived from baculoviral IAP repeat-containing protein 5 isoform 2 (BIRC5) and myc proto-oncogene protein (MYC) were significantly increased in nonsmall cell lung cancer (NSCLC). This study was undertaken to replicate this initial work in an independent sample. An enzyme-linked immunosorbent assay (ELISA) was developed in-house to examine plasma IgG antibodies for three linear peptide antigens derived from BIRC5a, BIRC5b, and MYC in 211 patients with NSCLC and 200 control subjects...
May 2018: FEBS Open Bio
https://www.readbyqxmd.com/read/29720822/herbal-medicines-showing-synergistic-effects-with-tumor-necrosis-factor-related-apoptosis-inducing-ligand-trail-against-a549-trail-resistant-lung-cancer-cells-a-screening-study
#13
Shuen Cheng Chiang, Yeon-Jung Choi, Shi-Eun Kang, Miyong Yun, Beom-Joon Lee
Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine that activates apoptosis through death receptors on the cell surface and is regarded as a potential anticancer agent. However, many cancer cells are resistant to TRAIL-induced apoptosis. Objective: The aim is to identify the herbal medicines that could help overcome resistance in TRAIL-resistant lung cancer cells. Materials and Methods: TRAIL-resistant A549 cells and 13 herbal medicines with known apoptosis-related anticancer effects were used in this study: Clematidis Radix , Corydalis Tuber Rhizoma , Paeoniae Radix Rubra , Corni Fructus , Curcumae longae Rhizoma (CLR) , Moutan Cortex , Salviae miltiorrhizae Radix , Phellodendri Cortex , Farfarae Flos , Paeoniae Radix Alba , Angelicae gigantis Radix , Coptidis Rhizoma (CR), and Taraxaci Herba ...
April 2018: Pharmacognosy Magazine
https://www.readbyqxmd.com/read/29696151/effectiveness-of-treatment-with-endostatin-in-combination-with-emcitabine-carboplatin-and-gemcitabine-in-patients-with-advanced-non-small-cell-lung-cancer-a-retrospective-study
#14
Xun Yu, Lemeng Zhang, Jianhua Chen
This study investigated the clinical efficacy, safety and tolerance of endostatin combined with gemcitabine and carboplatin for patients with advanced nonsmall cell lung cancer (NSCLC). From January 2010 to January 2014, 49 patients with advanced NSCLC were retrospectively evaluated; we defined 2 subgroups: a combination group (chemotherapy + anti-angiogenic therapy) and a chemotherapy group (chemotherapy only). The cases in the chemotherapy group received treatment with gemcitabine and carboplatin only, whereas the cases in the combination group received endostatin in combination with gemcitabine and carboplatin...
2018: Open Medicine (Warsaw, Poland)
https://www.readbyqxmd.com/read/29692997/efficacy-of-next-treatment-received-after-nivolumab-progression-in-patients-with-advanced-nonsmall-cell-lung-cancer
#15
Adrien Costantini, Jennifer Corny, Vincent Fallet, Sophie Renet, Sylvie Friard, Christos Chouaid, Boris Duchemann, Etienne Giroux-Leprieur, Laurent Taillade, Ludovic Doucet, Marina Nguenang, Stéphane Jouveshomme, Marie Wislez, Jean Tredaniel, Jacques Cadranel
Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aimed to evaluate the efficacy of nivolumab and of next treatment received after nivolumab progression in patients with advanced NSCLC. Our multicentre retrospective study included all patients receiving nivolumab between January and December 2015. The primary end-point was progression-free survival (PFS) of treatment given after nivolumab...
April 2018: ERJ Open Research
https://www.readbyqxmd.com/read/29692628/the-association-of-polymorphisms-in-mirnas-with-nonsmall-cell-lung-cancer-in-a-han-chinese-population
#16
Chuanyin Li, Yu Zhang, Yingfu Li, Qianli Ma, Shuyuan Liu, Yueting Yao, Fang Tan, Li Shi, Yufeng Yao
Background: MicroRNAs (miRNAs) have been demonstrated to play important roles in cancer progression. Recently, studies have revealed that polymorphisms in miRNAs might be associated with cancer susceptibility. Materials and methods: In the current study, we investigated the associations of single nucleotide polymorphisms (SNPs) in miRNAs (rs11134527 in pri-miR-218-2 , rs74693964 in pri-miR-145 , rs6062251 in pri-miR-133a-2 , and rs4705343 in pri-miR-143 ) with nonsmall cell lung cancer (NSCLC) in a Han population from Yunnan Province, Southwest China using a binary logistic regression analysis...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29692625/histological-subtype-of-lung-cancer-affects-acceptance-of-illness-severity-of-pain-and-quality-of-life
#17
Jacek Polański, Mariusz Chabowski, Beata Jankowska-Polańska, Dariusz Janczak, Joanna Rosińczuk
Introduction: Histologic classification of lung cancer plays an important role in clinical practice. Two main histological subtype of lung cancer: small-cell lung cancer (SCLC) and nonsmall-cell lung cancer (NSCLC) differ in terms of invasiveness, response to treatment, and risk factors, among others. Aims: To evaluate differences in acceptance of illness, level of perceived pain, and quality of life (QoL) between patients with SCLC and NSCLC. Materials and methods: Two hundred and fifty-seven lung cancer patients, who were treated in 2015, completed Acceptance of Illness Scale, Visual Analog Scale for pain, and European Organization for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire and European Organization for Research and Treatment of Cancer 13-item Lung Cancer specific Quality of Life Questionnaire...
2018: Journal of Pain Research
https://www.readbyqxmd.com/read/29676470/role-of-mirnas-in-lung-cancer
#18
REVIEW
Arif Uddin, Supriyo Chakraborty
Lung cancer (LC) is the leading cause of cancer-related deaths all over the world, among both men and women, with an incidence of over 200,000 new cases per year coupled with a very high mortality rate. LC comprises of two major clinicopathological categories: small-cell (SCLC) and nonsmall-cell lung carcinoma (NSCLC). The microRNAs (miRNAs) are small noncoding RNAs, usually 18-25 nucleotides long, which repress protein translation through binding to complementary target mRNAs. The miRNAs regulate many biological processes including cell cycle regulation, cellular growth, proliferation, differentiation, apoptosis, metabolism, neuronal patterning, and aging...
April 20, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29672399/minimally-invasive-lobectomy-is-associated-with-lower-noncancer-specific-mortality-in-elderly-patients-a-propensity-score-matched-competing-risks-analysis
#19
Boris Hristov, Takashi Eguchi, Sarina Bains, Joe Dycoco, Kay See Tan, James M Isbell, Bernard J Park, David R Jones, Prasad S Adusumilli
OBJECTIVE: To investigate cancer- and noncancer-specific mortality following lobectomy by minimally invasive surgery (MIS) versus open thoracotomy in elderly patients with nonsmall cell lung cancer (NSCLC). BACKGROUND: Two-thirds of patients with NSCLC are ≥65 years of age. As age increases, the risk of competing events, such as noncancer death, also increases. METHODS: Elderly patients (≥65 yrs of age) who have undergone curative-intent lobectomy for stage I-III NSCLC without induction therapy (2002-2013) were included (n=1,303)...
April 18, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29600239/clinical-outcome-study-of-crizotinib-in-immunohistochemistry-proven-echinoderm-microtubule-associated-protein-like-4-anaplastic-lymphoma-kinase-fusion-gene-among-indian-patients-with-adenocarcinoma-lung
#20
Ullas Batra, Mohit Aggarwal, Parveen Jain, Pankaj Goyal, Abhishek Yadav, Udip Maheshwari, Anurag Mehta
Aims: The anaplastic lymphoma kinase (ALK) Break Apart FISH Probe Kit and Ventana anti-ALK (D5F3) CDx immunohistochemistry (IHC) assay are the Food and Drug Administration-approved companion diagnostic for targeted therapy with the ALK inhibitor crizotinib in lung cancers. The aim of this study was to assess the efficacy and safety of twice daily crizotinib tablet (250 mg) in IHC-proven echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene among Indian patients with adenocarcinoma lung in the routine clinical practice...
January 2018: South Asian Journal of Cancer
keyword
keyword
55784
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"